Kenvue stock drops 10% on report RFK Jr. will link autism to Tylenol use during pregnancy

Kenvue Inc. shares fell over 10% on Friday following a Wall Street Journal report indicating that Health and Human Services Secretary Robert F. Kennedy Jr. is expected to link the company's Tylenol pain medication to autism in pregnant women in a report due this month. This potential finding, which also notes a folate-derived treatment for autism symptoms, presents a substantial market and reputational risk for Kenvue's flagship product.

Analysis

Kenvue Inc. (KVUE) experienced a significant share price decline of over 10% following a Wall Street Journal report about an anticipated announcement from Health and Human Services (HHS). The market's strongly negative reaction is a direct response to the expectation that an upcoming HHS report will formally link prenatal use of Kenvue's flagship product, Tylenol, with autism. This event creates a material and immediate threat to the company's fundamentals, introducing a high probability of future litigation, regulatory scrutiny, and severe reputational damage to a core consumer brand. The situation is characterized by a high degree of uncertainty, as the market is reacting to a report about a *future* report, but the magnitude of the stock's drop signals that investors are pricing in a worst-case scenario for one of Kenvue's most critical revenue streams. The secondary mention of a potential folate-derived treatment does little to mitigate the primary risk posed to the Tylenol brand.

Key Decisions for Investors

• Given the severe stock decline and high uncertainty, investors should prepare for continued volatility and consider hedging or reducing exposure until the official HHS report is released and its contents can be fully assessed.
• The news introduces substantial long-tail risk from potential litigation and brand erosion, warranting a fundamental reassessment of Kenvue's long-term valuation and market position.
• Traders should avoid making speculative bets based on the current news, as the stock's trajectory is now highly dependent on the specific language and scientific evidence presented in the forthcoming government report, which could differ from current expectations.